Ocugen’s OCU410 Trial Now Recruiting — But the Verdict Is Still Two Years Away
The first patient has been dosed in Ocugen's global Phase 3 registration study for OCU410, the company's one-time gene therapy ...
Tag: Ocugen
Ocugen Prepares for Pivotal Conference Season with Promising Retinal Gene Therapy Data
A string of positive clinical readouts has given Ocugen a clear narrative to bring to ophthalmology’s biggest gatherings this month. ...
Ocugen’s 673% Analyst Upside Hinges on a Tight Window of Clinical Data and Regulatory Submissions
A €10 price target with the stock trading at €1.29. That 673% gap isn't a typo — it's the distance ...
Ocugen’s Modifier Gene Therapy Targets Dozens of Blindness-Causing Mutations with One Drug
A single drug that could treat inherited blindness regardless of which gene is broken — that is the audacious promise ...
Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing
Ocugen has quietly reshaped its financial outlook. In May, the company placed $130 million in convertible notes, carrying a 6.75% ...
Ocugen’s Insider and Institutional Conviction Rises as a Dense Timeline of Gene Therapy Catalysts Approaches
Ocugen enters a make-or-break stretch that will test both its science and its stock. The gene therapy developer, which has ...
Ocugen’s CFO Bets on Her Own Stock as a Packed Conference Schedule Previews a Pivotal Summer
The clinical calendar is tightening for Ocugen, and the stock is starting to stir in anticipation. Shares closed the week ...
Ocugen Faces a Moment of Truth as Clinical Catalysts Collide With a 55% Plunge
The divergence between Ocugen's scientific trajectory and its stock price has rarely been starker. The biotech's shares closed at €1.05 ...
Ocugen’s Mutation-Agnostic Gene Therapy Edges Toward FDA Filing as $130M Financing Secures Runway to 2028
Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400, ...
Ocugen’s Data-Driven Countdown: Three Parallel Catalysts Converge in Q3 2026
Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company ...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
